Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Bionic cell membrane-inner core nanoparticle as well as preparation method and application thereof

A nanoparticle and cell membrane technology, applied in the direction of nanotechnology, nanotechnology, nanomedicine, etc., can solve the problems of high preparation cost and limited application, and achieve the effect of improving effectiveness, reducing drug concentration, and simple and efficient preparation method

Pending Publication Date: 2022-03-01
THE NAT CENT FOR NANOSCI & TECH NCNST OF CHINA
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the limitation that it is only suitable for ticagrelor, the administration method of intravenous infusion and the high cost of preparation also limit its application in clinical drug development to a certain extent.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Bionic cell membrane-inner core nanoparticle as well as preparation method and application thereof
  • Bionic cell membrane-inner core nanoparticle as well as preparation method and application thereof
  • Bionic cell membrane-inner core nanoparticle as well as preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example 1

[0068] (1) Take fresh blood from Balb / c mice, add anticoagulant (anticoagulant: blood=3:7, v / v), centrifuge at 216g for 11min, separate red blood cell layer, and obtain platelet-rich plasma;

[0069] (2) Add platelet extraction buffer (1:1, v / v) to the platelet-rich plasma obtained in step (1), and centrifuge at 850g for 5min to obtain platelet precipitate;

[0070] (3) Add platelet purification buffer (1:1, v / v) to the platelet precipitate obtained in step (2), centrifuge at 1000 g for 5 min after resuspension, and obtain purified platelets;

[0071] (4) The purified platelets obtained in step (3) were repeatedly frozen and thawed at -80° C. to 4° C. for three times, with an interval of 10 minutes between freezing and thawing, centrifuged at 10,000 g for 10 minutes, and resuspended to obtain platelet membranes.

preparation example 2

[0073] (1) Take fresh blood from Balb / c mice, add anticoagulant (anticoagulant: blood=1:5, v / v), centrifuge at 200g for 20min, separate red blood cell layer, and obtain platelet-rich plasma;

[0074] (2) Add platelet extraction buffer (2:1, v / v) to the platelet-rich plasma obtained in step (1), and centrifuge at 1200g for 2min to obtain platelet precipitates;

[0075] (3) Add platelet purification buffer (2:1, v / v) to the platelet precipitate obtained in step (2), and centrifuge at 800 g for 8 min after resuspending to obtain purified platelets;

[0076] (4) The purified platelets obtained in step (3) were repeatedly frozen and thawed four times at -80° C. to 4° C., with a freeze-thaw interval of 15 minutes, centrifuged at 5000 g for 20 minutes, and resuspended to obtain platelet membranes.

preparation example 3

[0078] (1) Take fresh blood from Balb / c mice, add anticoagulant (anticoagulant: blood=1:8, v / v), centrifuge at 230g for 5min, separate red blood cell layer, and obtain platelet-rich plasma;

[0079] (2) Add platelet extraction buffer (1:2, v / v) to the platelet-rich plasma obtained in step (1), and centrifuge at 600 g for 8 min to obtain platelet precipitates;

[0080] (3) Add platelet purification buffer (1:2, v / v) to the platelet precipitate obtained in step (2), centrifuge at 1500 g for 3 min after resuspension, and obtain purified platelets;

[0081] (4) The purified platelets obtained in step (3) were repeatedly frozen and thawed four times at -80° C. to 4° C., with a freeze-thaw interval of 15 minutes, centrifuged at 5000 g for 20 minutes, and resuspended to obtain platelet membranes.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Dispersionaaaaaaaaaa
Login to View More

Abstract

The invention relates to a biomimetic cell membrane-inner core nanoparticle as well as a preparation method and application thereof. The biomimetic cell membrane-inner core nanoparticle comprises an inert inner core and a biomimetic cell membrane coated outside the inert inner core. The invention develops the antithrombotic drug reversal agent which is effective for various antithrombotic drugs, high in safety, convenient to operate and low in preparation cost, the inert core is used as a support skeleton, and the bionic cell membrane is used as an antithrombotic drug adsorption layer; the receptor expressed by the bionic cell membrane is used as a bait to be combined with an antithrombotic drug to reduce the blood concentration in a free form, so that the antithrombotic effect can be effectively reduced; on the other hand, the biocompatibility of the nano particles can be enhanced through wrapping of the bionic cell membrane, and the probability that the nano particles are cleared by an organism is reduced.

Description

technical field [0001] The invention belongs to the technical field of nanomedicine, relates to a biomimetic cell membrane-core nanoparticle and its preparation method and application, in particular to a biomimetic cell membrane-core nanoparticle and a preparation method thereof and in the preparation of a reversal agent for drugs with antithrombotic effect in the application. Background technique [0002] Cardiovascular and cerebrovascular diseases represented by acute myocardial infarction and ischemic stroke seriously endanger human health. Thrombus induced by platelet activation plays a crucial role in the pathogenesis of these diseases. Therefore, antithrombotic drugs are the most common choice for the treatment of cardiovascular and cerebrovascular diseases. Antithrombotic drugs mainly include antiplatelet drugs. Among them, in addition to the classic antiplatelet drug aspirin, the most widely used platelet adenosine diphosphate (ADP) receptor blockers such as clopi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/51A61K47/46A61K45/00A61K47/18A61K47/34A61P7/02B82Y5/00B82Y40/00
CPCA61K9/5068A61K45/00A61K47/18A61K47/34A61P7/02B82Y5/00B82Y40/00
Inventor 聂广军张银龙徐俊超王春岭
Owner THE NAT CENT FOR NANOSCI & TECH NCNST OF CHINA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com